TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of mild Alzheimer's Disease~* Mini-Mental State Examination (MMSE) scores between 20 and 26 (inclusive)~* Clinical dementia rating (CDR) scores of 0.5 or 1~* Other inclusion criteria apply~Exclusion Criteria:~* Clinically significant neurological disease other than Alzheimer's disease~* Major psychiatric disorder~* Severe systemic disease~* Serious adverse reactions to any vaccine~* Other exclusion criteria apply

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 3 priming doses followed by 4 boosters (Type: EXPERIMENTAL): Subjects will receive 7 doses of UB-311.
- 3 priming doses followed by 2 boosters (Type: EXPERIMENTAL): Subjects will receive 5 doses of UB-311 and 2 doses of placebo.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will receive 7 doses of placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of 3 Techniques for Ultrasound-guided Femoral Nerve Catheter Insertion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 80 years old at time of surgery.~* Male or female patients undergoing total knee replacement under either general or neuraxial anesthesia (spinal or epidural). Intraoperative, patients will receive spinal anesthetics with 15 mg bupivacaine and 25mcg of fentanyl intrathecally.~Exclusion Criteria:~* Current or recent drug abuse (within past 6 months).~* Pregnancy.~* Patient refuses regional analgesia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ultrasound guidance alone (Type: ACTIVE_COMPARATOR): The Tuohy needle was inserted in out-plane approach. Needle placement was considered adequate when the tip was visualized beneath the fascia iliaca; the catheter was then introduced 5 cm beyond the needle tip. Electrical stimulation was not used.
- Ultrasound guidance needle stimulation (Type: ACTIVE_COMPARATOR): For the ultrasound guidance and needle stimulation arm, the Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA (2 Hz, pulse width 0.1 msec). Subsequently, the catheter was threaded 5 cm beyond the needle tip without additional electrical stimulation
- Ultrasound guidance+catheter stimulation (Type: ACTIVE_COMPARATOR): For the ultrasound guidance and catheter stimulation group, the Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA. At that point, the peripheral nerve stimulator was then disconnected from the stimulating needle and connected to the proximal end of the catheter. The catheter was then advanced 5 cm past the needle tip. If the motor response disappeared during catheter advancement, the catheter was withdrawn slightly until the response returned. Needle orientation and catheter advancement were adjusted as necessary to elicit quadriceps contractions via the catheter with a stimulating current ≤0.5 mA.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 12 years of age or older with a minimum body weight of 40 kg~* Diagnosis of atopic dermatitis (AD) for at least 1 year and current status of moderate to severe disease (\>= the following scores: BSA 10%, IGA 3, EASI 16, Pruritus NRS severity 4)~* Recent history of inadequate response or inability to tolerate topical AD treatments or require systemic treatments for AD control~Exclusion Criteria:~* Unwilling to discontinue current AD medications prior to the study or require treatment with prohibited medications during the study~* Prior treatment with JAK inhibitors~* Other active nonAD inflammatory skin diseases or conditions affecting skin~* Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator~* Pregnant or breastfeeding women, or women of childbearing potential who are unwilling to use contraception

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-04965842 100 mg (Type: EXPERIMENTAL): None
- PF-04965842 200 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Evaluate Methods To Evaluate Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Lower back pain~* Male or female in generally good health, from 18 to 55 years of age (inclusive)~Exclusion Criteria:~* Pregnant or lactating~* Subject has evidence or history of radiculopathy, i.e. sciatica extending below the knee (numbness, tingling, or shooting pain), or other neurologic deficits (abnormal straight leg raise test, patellar reflexes, and/or bowel and bladder function);~* Subject has a history of previous back surgery;~* Subject has back pain resulting from traumatic injury involving physical evidence of bruising, swelling, or inflammation to the abdomen or low back area which occurred less than 48 hours prior to enrollment~* Has taken an investigational drug within the past 30 days prior to entering the study, or currently enrolled in another investigational study~* Is a member or relative of the study site staff, CRO or Sponsor organization directly involved with the study or had a household member or relative participate concurrently or previously in this study~* Has previously been enrolled in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Heat device
- 2 (Type: SHAM_COMPARATOR): Placebo arm
- 3 (Type: ACTIVE_COMPARATOR): Marketed analgesic
- 4 (Type: PLACEBO_COMPARATOR): (Oral) Placebo comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RSYR for Fatigue Reduction in Cancer Survivors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Pathological diagnosis of malignant tumors; 3 months without surgery, radiotherapy and chemotherapy, biological treatment; Hemoglobin \> 11g/L; Complete remission of the lesion, or recent review of the Disease is stable, the estimated survival time is more than 6 months; ECOG score is 0-2, fatigue score of the last 24 hours \> 4 ; Age is 18-65 years old; TCM syndrome differentiation for deficiency of qi; Liver, kidney function, electrolyte normal; Willing to join the group and sign the informed consent.~Exclusion Criteria:~Allergies to herbs and plant drugs; Uncontrollable diabetes, hypertension, TSH abnormalities, uncontrollable pain, and a history of myocardial infarction within 6 months; Scores of anxiety disorders and depression (HAD-D) were 11 or more, antidepressants and antioxidants were used in the past month; Breast cancer receptor positive patients took endocrine therapy drugs; Tonics were used in the past 2 weeks.; Children, pregnant and lactating women; Receiving anemia-related treatment; Chinese medicine syndrome differentiation with excessive heat; Unable to read or understand the scale.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- RSYYT decoction (Type: EXPERIMENTAL): RSYYT decoction Compound granules of traditional Chinese medicine
- Astragalus membranaceus (Type: EXPERIMENTAL): one herb decoction Compound granules of one herb (Astragalus membranaceus)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ReActiv8 Implantable Neurostimulation System for Chronic Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥22 years, ≤75 years~2. Chronic Low Back Pain that has persisted \>90 days prior to the baseline visit.~3. Continuing low back pain despite \>90 days of medical management.~4. Qualifying pain score.~5. Qualifying disability score.~6. Evidence of lumbar multifidus muscle dysfunction.~7. Be willing and capable of giving Informed Consent.~8. Ability to comply with the instructions for use and to operate ReActiv8, and to comply with this Clinical Investigation Plan.~9. Suitable for ReActiv8 surgery as determined by the implanting physician prior to inclusion.~Exclusion Criteria:~1. BMI \> 35~2. Back Pain characteristics:~   1. Any surgical correction procedure for scoliosis at any time, or a current clinical diagnosis of scoliosis.~  2. Lumbar spine stenosis, as defined by an anterior-posterior diameter of the spinal canal of \<10mm in subjects with lower extremity pain.~  3. Neurological deficit possibly associated with the back pain (e.g. foot drop).~  4. Back pain due to pelvic or visceral reasons (e.g.: endometriosis or fibroids) or infection (e.g.: post herpetic neuralgia).~  5. Back pain due to inflammation or damage to the spinal cord or adjacent structures (e.g. arachnoiditis or syringomyelia).~  6. Pathology seen on MRI that is clearly identified and is likely the cause of the CLBP that is amenable to surgery.~  7. Back pain due to vascular causes such as aortic aneurysm and dissection.~3. Any current indication for back surgery according to local institutional guidelines, or has indication for back surgery but cannot undergo surgery for other reasons.~4. Leg pain described as being worse than back pain, or radiculopathy (neuropathic pain) below the knee.~5. Source of pain is the sacroiliac joint as determined by the Investigator.~6. Drug use.~7. Surgical and other procedures exclusions.~8. Any prior diagnosis of lumbar vertebral compression fracture, lumbar pars fracture, or lumbar annular tear with disc protrusion that is amenable to surgery.~9. Planned surgery.~10. Co-morbid chronic pain conditions.~11. Other clinical conditions.~12. Psycho-social exclusions.~13. Protocol compliance exclusions.~14. General exclusions.

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): None
- Control (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria~1. Documented or participant-reported history of birch pollen-triggered allergic rhinitis symptoms, with or without conjunctivitis, for at least 2 years~2. Positive Skin prick test (SPT) with birch pollen extract in the screening period, as defined in the protocol~3. Positive Allergen-specific IgE (sIgE) tests for birch pollen and Bet v 1 in the screening period, as defined in the protocol~4. Willing and able to comply with clinic visits and study-related procedures~Key Exclusion Criteria:~1. Participation in a prior REGN5713-5714-5715 clinical trial~2. Recurrent or chronic rhinitis or sinusitis not associated with birch pollen season, or due to daily contact with other allergens causing symptoms that are expected to coincide with birch pollen season, as assessed by the investigator~3. Participants who anticipate major changes in allergen exposure in their home or work environments that are expected to coincide with the study assessments as assessed by the investigator~4. Persistent chronic or recurring acute infection requiring treatment with antibiotics, antivirals, or antifungals, or any untreated respiratory infections (at the discretion of the investigator) within 4 weeks prior to screening visit. Participants may be re-evaluated for eligibility after symptoms resolve~5. Documentation of active SARS-CoV-2 infection, as defined in the protocol~6. A clinical history of asthma with 2 or more asthma exacerbations requiring hospitalizations or systemic corticosteroids in the previous year~7. History of birch allergy immunotherapy as defined in the protocol~8. Use of anti-IgE or other biological therapy in treatment of asthma or allergy within 6 months prior to screening~NOTE: Other protocol defined Inclusion/Exclusion Criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- REGN5713-5714-5715 (Type: EXPERIMENTAL): REGN5713-5714-5715 administered subcutaneously
- Placebo Only (Type: PLACEBO_COMPARATOR): Placebo matching REGN5713-5714-5715 administered subcutaneously

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Community Wellness Program for Adults Living With Long-term Physical Disability

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 45 to 64 years of age at screening (turning 65 years after screening is ok);~* Able to read, speak, and understand English;~* Has a self-reported physician's diagnosis of long-term physical disability defined as:~  * a medical condition affecting the muscular or neurologic systems (eg, muscular dystrophy, multiple sclerosis, post-polio syndrome or spinal cord injury), and the condition:~ * creates functional disability (impairment in at least one activity of daily living (ADL) or at least one instrumental activity of daily living (IADL), as indicated by the Expanded Functional Disability Scale)~ * was present before age 40 years~* Able to participate via telephone;~* Has a goal in mind if randomized to the EW-D intervention;~* Has not participated in the original EnhanceWellness intervention group.~Exclusion Criteria:~* Under 45 years of age or 65 or older at screening;~* Unable to read, speak, or understand English;~* Does not have a neurological or muscular condition affecting physical function (e.g., persons with low back pain and shoulder pain would be excluded);~* Does not have functional disability;~* Disability onset after age 40 years;~* Significant cognitive impairment as defined by the Six-Item Screener;~* Psychiatric condition or symptoms that would interfere with participation, specifically:~  * Current, active suicidal ideation with current intent to harm oneself, or~ * Current schizophrenia, psychosis, or mania~* Unable to participate via telephone;~* Does not have a goal if randomized to the EW-D intervention;~* Has participated in the original EnhanceWellness intervention group.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- EnhanceWellness for Disability (EW-D) (Type: EXPERIMENTAL): Up to 10 sessions of a telephone-based intervention delivered over a six-month period.
- Wellness Education (Type: ACTIVE_COMPARATOR): Eight 45-minute sessions of telephone-based wellness education delivered over a six-month period.
- Control (Type: NO_INTERVENTION): Participant continues with their lives as they normally would.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Global Vascular Effects of Intermittent Pneumatic Compression-Pilot Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Category 1 subjects-healthy volunteers (no MRI required) INCLUSION (N-12) 21 -40 years male or female EXCLUSIONS History of CAD, MI, Cath,CABG,CTA, positive stress test HTN uncontrolled (SBP\>140 or DBP\>90) DM except diet controlled Cholesterol \>200 at screening Smoking last 10 years Acute Medical Illness Inflammatory Phlebitis Infection lower limbs Recent lower limb surgery~Category 2 subjects ( age matched without CAD)(no MRI required) INCLUSION (N-12) 50 plus male or female EXCLUSIONS History of CAD, MI, Cath,CABG,CTA, positive stress test HTN uncontrolled (SBP\>140 or DBP\>90) DM except diet controlled Cholesterol \>200 at screening Smoking last 10 years Acute Medical Illness Inflammatory Phlebitis Infection lower limbs Recent lower limb surgery~Category 3 subjects ( age matched with CAD)(no MRI required) INCLUSION (N-up to 5) 50 plus male or female documented CAD by cath, PTCI, CABG, CTA EXCLUSIONS History of CHF, DVT, PE Angina, active, needing nitrates Acute Medical Illness Inflammatory Phlebitis Infection lower limbs Recent lower limb surgery~Category 4 subjects with MRI (original group) INCLUSIONS(N=12) 50 plus male or female documented CAD by cath, PTCI, CABG, CTA EXCLUSIONS History of CHF, DVT, PE Angina, active, needing nitrates Atrial Fib BMI\>35 (MRI) MRI contraindications pregnancy Chronic Inflammatory Disease Acute Medical Illness Inflammatory Phlebitis Infection lower limbs recent lower limb surgery

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Intermittent leg compression (Type: OTHER): Intermittent leg compression daily for 3 hrs a day for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BAY94-9027 PK Study Comparing to Another Long Acting Product

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males, age 18 to 65 years.~* Subjects with Severe Hemophilia A with a documented plasma FVIII level of \< 1%~* ≥ 150 exposure days with FVIII concentrate(s) as supported by medical records~Exclusion Criteria:~* Evidence of current or past inhibitor antibody:~* History of any congenital or acquired coagulation disorders other than hemophilia A.~* Platelet count \<75,000/mm\*3.~* Abnormal renal function (serum creatinine \>2 x the upper limit of the normal range).~* Active liver disease verified by medical history or persistently elevated alanine aminotransferase or aspartate aminotransferase \>5 x the upper limit of the normal range or severe liver disease as evidenced by, but not limited to any of the following: International Normalized Ratio \>1.4, hypoalbuminemia, portal vein hypertension including presence of otherwise unexplained splenomegaly and history of esophageal varices.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- BAY94-9027 and Elocta (Type: EXPERIMENTAL): Subjects received two treatments: 60 IU/kg BAY94-9027 in the first period, followed by 60 IU/kg Elocta in the second period, with a washout period before each treatment
- Elocta and BAY94-9027 (Type: EXPERIMENTAL): Subjects received two treatments: 60 IU/kg Elocta in the first period, followed by 60 IU/kg BAY94-9027 in the second period, with a washout period before each treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Fruit/Vegetable Drinks on the Human Intestine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-50 years of age at screen~2. Subjects must read and sign the Institutional Review Board-approved written informed consent prior to the initiation of any study specific procedures or enrollment. A subject will be excluded for any condition that might compromise the ability to give truly informed consent.~Exclusion Criteria:~1. Any subject with a history of diabetes mellitus on medications, hyperlipidemia on medications, or other serious medical condition, such as chronic hepatic or renal disease, bleeding disorder, congestive heart disease, chronic diarrhea disorders, myocardial infarction, coronary artery bypass graft, angioplasty within 6 months prior to screening, current diagnosis of uncontrolled hypertension (defined as systolic BP\>160mmHg, diastolic BP\>95mmHg), active or chronic gastrointestinal disorders, bulimia, anorexia, or endocrine diseases (except thyroid disease requiring medication) as indicated by medical history or routine physical examination.~2. Any subject with a screening laboratory value outside of the laboratory normal range that is considered clinically significant for study participation by the investigator.~3. Any subject who currently uses tobacco products.~4. Any history of gastrointestinal disease except for appendectomy~5. No antibiotics or laxatives use during the 2 months before the study.~6. Any allergies to nuts~7. Any subject who is unable or unwilling to comply with the study protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- pressed juice 6 bottles (Type: OTHER): Subjects will consume pressed juice daily for 3 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete